When is lanreotide preferred over octreotide in GI neuroendocrine tumors?

As far as I am concerned, the drugs are equally effective, assuming the drugs get delivered correctly. The advantages of lanreotide are, as others have mentioned, a more reliable delivery method being given SC instead of IM. Also, lanreotide has faster absorption and it takes a shorter time to achieve the needed blood levels.

Is that really an issue? Let's look at the data. A study of 50 patients receiving IM injections and having a CT afterwards showed that a minority, only 35%, had the drug actually injected IM. In this study, 1 mL of air was injected along with the drug so it was easy to see where the injections ended up.

Well, how about octreotide LAR per se? A study of 158 patients receiving 328 injections at MD Anderson showed results n...

Currently, there is no evidence to favor one SSA over the other. Both randomized trials (PROMID and CLARINET) showed improved PFS with octreotide and lanreotide. However, both trials had differences in patient population, functionality, and liver tumor burden, we can't select one SSA over the other according to these findings unless we have a prospective trial comparing both of them in a randomized fashion. Very limited situations we may consider lanreotide over octreotide. For patients with higher BMI, we can consider SC lanreotide for better bioavailability. A phase II CLARINET FORTE study showed that an increased dose frequency of lanreotide from a first line standard dose of 120 mg every 28 days, to an increased dose of 120 mg every 14 ...

Obesity can be an issue for IM injections with Sandostatin. Tough to reach the muscle and a good reason to switch to a sub-q formulation.

Patient preference. I had a patient who developed an abscess after Sandostatin, which is a deep IM injection.